PDF

Theranostics 2024; 14(15):5745-5761. doi:10.7150/thno.100116 This issue Cite

Research Paper

Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies

Shadi A. Esfahani^1,2* , Hua Ma^1,3*, Shriya Krishna¹, Sergey Shuvaev^1,3, Mark Sabbagh³, Caitlin Deffler², Nicholas Rotile¹, Jonah Weigand-Whittier¹, Iris Y. Zhou^1,3, Ciprian Catana^1,3, Onofrio A. Catalano¹, David T. Ting⁴, Pedram Heidari^1,2, Eric Abston⁵, Michael Lanuti⁵, Genevieve M. Boland⁶, Priyanka Pathak⁴, Hannah Roberts⁷, Kenneth K. Tanabe⁶, Motaz Qadan⁶, Carlos Fernandez-del Castillo⁶, Angela Shih⁸, Aparna R. Parikh⁴, Colin D. Weekes⁴, Theodore S. Hong⁷, Peter Caravan^1,3

1. Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
2. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
3. Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
4. Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
5. Division of Thoracic Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
6. Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
7. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
8. Department of Pathology, Massachusetts General Hospital, Boston, Harvard Medical School, Massachusetts, USA.
*Equal contributions.

✉ Corresponding author: Shadi Abdar Esfahani, MD, MPH, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, 55 Fruit St, White 427J, Boston, MA, 02114. Email: Esfahani.shadiharvard.edu; Tel.: 617-726-1758. More

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an invasive and rapidly progressive malignancy. A major challenge in patient management is the lack of a reliable imaging tool to monitor tumor response to treatment. Tumor-associated fibrosis characterized by high type I collagen is a hallmark of PDAC, and fibrosis further increases in response to neoadjuvant chemoradiotherapy (CRT). We hypothesized that molecular positron emission tomography (PET) using a type I collagen-specific imaging probe, ⁶⁸Ga-CBP8 can detect and measure changes in tumor fibrosis in response to standard treatment in mouse models and patients with PDAC.

Methods: We evaluated the specificity of ⁶⁸Ga-CBP8 PET to tumor collagen and its ability to differentiate responders from non-responders based on the dynamic changes of fibrosis in nude mouse models of human PDAC including FOLFIRNOX-sensitive (PANC-1 and PDAC6) and FOLFIRINOX-resistant (SU.86.86). Next, we demonstrated the specificity and sensitivity of ⁶⁸Ga-CBP8 to the deposited collagen in resected human PDAC and pancreas tissues. Eight male participant (49-65 y) with newly diagnosed PDAC underwent dynamic ⁶⁸Ga-CBP8 PET/MRI, and five underwent follow up ⁶⁸Ga-CBP8 PET/MRI after completing standard CRT. PET parameters were correlated with tumor collagen content and markers of response on histology.

Results: ⁶⁸Ga-CBP8 showed specific binding to PDAC compared to non-binding ⁶⁸Ga-CNBP probe in two mouse models of PDAC using PET imaging and to resected human PDAC using autoradiography (P < 0.05 for all comparisons). ⁶⁸Ga-CBP8 PET showed 2-fold higher tumor signal in mouse models following FOLFIRINOX treatment in PANC-1 and PDAC6 models (P < 0.01), but no significant increase after treatment in FOLFIRINOX resistant SU.86.86 model. ⁶⁸Ga-CBP8 binding to resected human PDAC was significantly higher (P < 0.0001) in treated versus untreated tissue. PET/MRI of PDAC patients prior to CRT showed significantly higher ⁶⁸Ga-CBP8 uptake in tumor compared to pancreas (SUV_mean: 2.35 ± 0.36 vs. 1.99 ± 0.25, P = 0.036, n = 8). PET tumor values significantly increased following CRT compared to untreated tumors (SUV_mean: 2.83 ± 0.30 vs. 2.25 ± 0.41, P = 0.01, n = 5). Collagen deposition significantly increased in response to CRT (59 ± 9% vs. 30 ± 9%, P=0.0005 in treated vs. untreated tumors). Tumor and pancreas collagen content showed a positive direct correlation with SUV_mean (R² = 0.54, P = 0.0007).

Conclusions: This study demonstrates the specificity of ⁶⁸Ga-CBP8 PET to tumor type I collagen and its ability to differentiate responders from non-responders based on the dynamic changes of fibrosis in PDAC. The results highlight the potential use of collagen PET as a non-invasive tool for monitoring response to treatment in patients with PDAC.

Keywords: pancreatic cancer, type I collagen, PET imaging, treatment response, fibrosis

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a poor prognosis and a five-year overall survival of less than 9% [1, 2]. Over the past two decades, the prevalence and mortality of PDAC have markedly increased and it is projected to become the second leading cause of cancer-related deaths before 2030 [3]. At the moment the only hope for cure is complete surgical resection, but only 10-15% of patients have resectable disease at presentation [4, 5]. To increase the number of patients eligible for resection and improve outcomes, neoadjuvant chemoradiotherapy (CRT) has become the standard in patients with borderline resectable or locally advanced PDAC to downstage the tumor, expand surgical indications, and reduce nodal involvement [6-9]. Chemotherapy regimens such as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin), and gemcitabine plus nab-paclitaxel are commonly used to treat patients with metastatic disease. One of the major challenges in the management of PDAC is that standard imaging methods have poor reliability for the assessment of PDAC response to treatment because they do not accurately show the change in size or resectability of the residual tumor tissue [10-14]. Although standard computer tomography (CT) or magnetic resonance imaging (MRI) is often performed at least two months apart, the changes in tumor size or morphology are not often precisely revealed [15]. A large majority of patients need to undergo exploratory surgery and repetitive biopsies for post-treatment staging [10, 16, 17]. Thus, there is an unmet need for the development of non-invasive imaging biomarkers to accurately monitor treatment response in PDAC.

Tumor fibrosis is a feature of PDAC caused by deposition of increased extracellular matrix (ECM), mainly type I collagen [18]. While the fibrotic stroma in PDAC has often been proposed as a barrier to effective chemotherapy [18, 19], previous studies have shown that a positive response to neoadjuvant chemotherapy or CRT actually increases tumor fibrosis and is associated with improved outcomes in PDAC [14, 20]. Therefore, measuring the change in tumor fibrosis could be used as a unique tool for PDAC response assessment to guide clinical management decisions and prognostication. Unfortunately, quantifying the temporal changes of tumor fibrosis is not possible with currently available conventional imaging modalities [10]. A translatable molecular imaging tool is more suited to address this unmet need.

Our laboratory has developed [21, 22] and optimized a type I collagen specific positron emission tomography (PET) imaging probe, ⁶⁸Ga-CBP8, and has validated it in multiple animal models of fibrotic diseases [21-24]. This PET probe has recently been translated in healthy volunteers and patients with idiopathic pulmonary fibrosis and radiation induced lung injury [25-27]. This study aims to develop a ⁶⁸Ga-CBP8 PET image-guided paradigm for monitoring PDAC treatment response.

Methods

Study design

The overall goal of this study was to validate, optimize, and translate quantitative molecular imaging of tumor-associated fibrosis for non-invasive evaluation of treatment response in PDAC using a type I collagen PET imaging probe ⁶⁸Ga-CBP8. We addressed these goals by 1) developing and selecting mouse models of human PDAC that were sensitive or resistant to standard-of-care FOLFIRNOX chemotherapy regimen, 2) determining the specificity of the ⁶⁸Ga-CBP8 PET probe in binding to tumor collagen compared with a linear peptide non-binding control PET probe ⁶⁸Ga-CNBP in untreated and in FOLFIRINOX- and vehicle-treated mouse models of PDAC over multiple treatment time points, 3) determining the optimal time of ⁶⁸Ga-CBP8 PET acquisition in mouse tumor models, 4) confirming the ability and specificity of ⁶⁸Ga-CBP8 to target collagen in human PDAC specimens ex vivo and lastly, 5) demonstrating the feasibility of ⁶⁸Ga-CBP8 PET imaging for evaluation of response to standard neoadjuvant chemoradiotherapy in patients with PDAC. The animal experiments were approved and conducted per Institutional Animal Care and Use Committee (IACUC) guidelines, in accordance with ARRIVE guidelines (institutional protocol 2019N000139). Animals were randomly assigned to different groups. The human PDAC tumor and pancreas tissues were obtained from patients who underwent surgical resection at our institution and consented under a discarded tissue institutional protocol 02-240. The clinical feasibility study was performed in an open-label non-randomized fashion (patients consented and were recruited under protocol 2020P001899, NCT04485286). Pre-clinical and clinical PET image and histological analyses were performed blinded to the type of tumor, type of treatment, and imaging timepoint. The inclusion and exclusion criteria for the clinical study are detailed in Table 1. The sample size for each experiment and analysis method are mentioned in the results section and figure legends.

In vitro cell culture, treatment, and viability assay

Human primary PDAC cells PANC-1 (ATCC), patient-derived metastatic cells PDAC6 (obtained from Dr. Ting's laboratory [28], and SU.86.86 (ATCC) were used. Cells were cultured in DMEM medium (for PANC-1 and PDAC6, ATCC) and RPMI (for SU.86.86, ATCC) supplemented with 10% fetal bovine serum (ThermoFisher) and 1% penicillin-streptomycin (ThermoFisher) at 37ºC and 5% CO₂. Cells were tested for mycoplasma by PCR monthly.

A cell viability assay was performed to assess the level of sensitivity of the PDAC cells to FOLFIRINOX. Cells were cultured in 96-well plates with 100 µL of phenol-red-free medium. FOLFIRINOX drugs were dissolved in water to prepare stock solutions with 1000X concentration of each drug and then combined in a ratio similar to the routine clinical usage, with 1X defined as 3 μM 5-fluorouracil, 0.4 μM irinotecan, 0.3 μM oxaliplatin and 0.3 μM of calcium folinate (Sigma Aldrich) in the culture medium [28]. When the cells reached approximately 90% confluency (5 x 10³ cells/well), FOLFIRINOX (0.001, 0.01, 0.1, 1, and 10 relative to 1X ratios) or vehicle (water) was added to the wells (3 wells per cell line and treatment group). Cell viability assay was performed at 24 and 48 h after treatment initiation using methods previously described [29]. Briefly, the medium was removed, and cells were rinsed with phosphate buffered saline (PBS, Fisher Scientific). Subsequently, 10 µL of tetrazolium salt WST-1 (Sigma Aldrich) was added to 100 µL of the medium in each well. Cells were incubated for 30 min at 37 °C according to the manufacturer's protocol. The absorbance of the samples against a background control well as blank was measured at the wavelength of 450 nm using the BioTek Cytation-5 Imaging Reader (Winooski, VT, USA). The viability of each cell line was defined as the percentage of signal from the FOLFIRNOX-treated relative to the vehicle-treated wells.

Mouse model of PDAC and FOLRINOX treatment

A total of 108 male athymic nude mice (Crl:NU(NCr)-Foxn1nu, strain 490, 6-8 week old, Charles River Laboratories, MA, USA) were used. Approximately 1-5 x10⁶ PDAC cells were mixed with Matrigel (BD Biosciences) in a total volume of 100 µL 1:1 (v/v) and injected in the subcutaneous space of the mice over the left shoulder [30]. Tumor growth was monitored by calipers every 3 days and reported as volume = (π/6) x length x width² (mm³) [31]. When the tumors reached 100-250 mm³, mice were randomly assigned to the experimental groups.

Treatment was performed with tail vein injection of FOLFIRINOX (50 mg/kg leucovorin, 25 mg/kg fluorouracil, 25 mg/kg irinotecan, 5 mg/kg oxaliplatin dissolved in saline at a total volume of less than 150 µL) or vehicle (normal saline, less than 150 µL volume) every 3 days for up to a total of 8 treatment administrations [14].

⁶⁸Ga-CBP8 and ⁶⁸Ga-CNBP PET probe synthesis and biodistribution analysis

The collagen-binding peptide in CPB8 is a 16 amino-acid peptide with a 10 amino acid disulfide bridged cyclic component [21, 22]. A linear control collagen non-binding peptide, CNBP was synthesized by reductive cleavage of the disulfide bond with the subsequent alkylation using iodoacetate as previously described [22]. For the synthesis of ⁶⁸Ga-CBP8 and ⁶⁸Ga-CNBP PET probes, ⁶⁸GaCl3 was eluted from a ⁶⁸Ge/⁶⁸Ga generator (Galli Eo TM, IRE-Elit, Fleurus, Belgium) with 1.1 mL of 0.1 mol/L hydrochloric acid, and ⁶⁸GaCl₃ (414 ± 55 MBq) was mixed with 100 µL of aqueous solution of CBP8 (or CNBP, 1 mmol/L) and 100 µL of sodium acetate buffer (pH 5.5, 1 M), and the mixture was heated to 95 °C for 15 min followed by cooling down at room temperature for 5 min. Sterile PBS and aqueous sodium hydroxide (1 M) were added to adjust the pH to 6.5-7 [22]. The radiochemical purity of the final solution was ≥ 99% for ⁶⁸Ga-CBP8 and ≥ 97% for ⁶⁸Ga-CNBP, as determined by radio-HPLC analysis (Agilent 1100 Series).

To study the biodistribution patterns of the collagen specific ⁶⁸Ga-CBP8 and control ⁶⁸Ga-CNBP probes, non-tumor-bearing male nude mice were injected with 4 MBq of either probe intravenously. At 1 h and 4 h post-injection, mice (16 total, n = 4 per probe type and time point) were euthanized and blood and different organs were extracted. The tissues were weighed and residual radioactivity in each was measured in the gamma counter (Wizard2, Perkin Elmer) and reported as the percentage of injected dose per gram (%ID/g).

In vivo PET/MRI of PDAC animal models and PET data analysis

PET/MRI acquisition was performed using a Bruker Si 198 PET insert inside a Bruker 4.7T MRI scanner. Animals were anesthetized by inhalation of air/oxygen mixture and isoflurane (5% for induction and 1.5% for maintenance) via a face mask, and placed in a custom-built cradle with body temperature maintained at 37 °C. PET images were acquired in list mode from 0 to 60 min after tail vein injection of the ⁶⁸Ga-CBP8 (11 - 20 MBq) or ⁶⁸Ga-CNBP (11 - 15 MBq) in a single bed position. The MR images were acquired simultaneously for accurate anatomic localization. The sequences include T1-weighted Fast Low Angle Shot (T1w-FLASH) [Repetition time / Echo time / Flip angle = 21 ms/ 3 ms/ 12°, 0.4 mm isotropic spatial resolution, field of view = 85 mm × 65 mm] and T2-weighted Rapid Acquisition with Relaxation Enhancement (T2w-RARE) [Repetition time / Echo time / Flip angle = 1.4 s / 48 ms / 180°; resolution = 0.25 x 0.25 x 1 mm³, FOV 85 × 65 mm²]. Data was reconstructed using methods previously described [31]. Images were analyzed using AMIDE software version 1.0.4. Three-dimensional regions of interest (ROI) were manually drawn over the tumors and left ventricle (as blood pool) guided by MRI. Standard PET uptake values were measured as the percentage of injected dosage per volume (%ID/cc).

Evaluation of the specificity of ⁶⁸Ga-CBP8 PET to tumor collagen and determination of the optimal imaging time

To assess the specificity of ⁶⁸Ga-CBP8 to type I collagen in the tumor ECM, PANC-1 and PDAC6 tumor-bearing mice (n = 7-8/group) underwent dynamic PET imaging at 0 to 60 min after intravenous injection of ⁶⁸Ga-CBP8 or ⁶⁸Ga-CNBP probes (3.7-11 MBq, i.v.), in a random order over 2 consecutive days. The tumor uptake (%ID/cc) was compared between the two PET probes over time. At 30 min post-injection, the tumor-to-blood PET ratio reached above 1, and therefore, 30-60 min post-injection was determined as an optimal time for shorter static imaging in the subsequent experiments. After PET, the animals were euthanized and the tissues were harvested. The extracted tumor tissue slides were stained with Picro-Sirius Red (PSR), and tumor collagen content was correlated with the PET probe uptake for each probe type.

To confirm the specificity of ⁶⁸Ga-CBP8 PET to changes in tumor collagen as compared to other factors such as a change in tumor vascular permeability over the course of treatment with chemotherapy, an additional group of PANC-1 tumor-bearing mice (n = 6) underwent PET imaging at 30-60 min after injection of ⁶⁸Ga-CBP8 or ⁶⁸Ga-CNBP probes prior to treatment, 9-10, and 15-16-days after treatment with FOLFIRINOX. Probes were injected in a random order on 2 consecutive days. The tumor PET probe uptake values were compared between the two probes on each day of the scan.

Evaluation of the ability of ⁶⁸Ga-CBP8 PET to monitor PDAC response to chemotherapy

Mice implanted with PDAC6, PANC-1, or SU.86.86 cells were randomized into 2 groups for treatment with FOLFIRINOX or vehicle every 3 days for up to 24 days. Animals in each group underwent PET/MRI with ⁶⁸Ga-CBP8 at baseline, 9- and 15-days post-treatment (n = 4-8/group). Tumor growth was monitored every 3 days for a total of 24 days. Tumor PET uptake values and growth curves were compared among multiple time points for each tumor type and treatment group.

Ex vivo evaluation of ⁶⁸Ga-CBP8 Probe for quantification of human tumor fibrosis by autoradiography

Fresh resected excess human tumors and adjacent pancreas tissues were obtained. The tissues were cut into small pieces of 30-50 μm thickness and rinsed with sterile PBS at room temperature. Each tissue was incubated with 0.5 MBq of either ⁶⁸Ga-CBP8 or the control ⁶⁸Ga-CNBP probe on a rotating shaker for 30 min. Following three times of rinses with PBS for a total of 3 min, the tissues were allowed to dry at room temperature. The radioactivity within the tissues was evaluated on an autoradiography system (Perkin Elmer). On the following day, the same protocol was performed by incubation of the same tissues with the other probe type. Acquired images were analyzed using ImageJ software (version 1.5.3, NIH, Bethesda, USA) by drawing an ROI over the tissues and recording a mean arbitrary signal.

Feasibility evaluation of ⁶⁸Ga-CBP8 PET/MRI for assessment of treatment response in patients with PDAC

Study participants with biopsy-proven borderline resectable or locally advanced PDAC were consented from July 2021 to March 2023 and enrolled in the study if the criteria were met (Table 1). Patients underwent a baseline ⁶⁸Ga-CBP8 PET/MRI of the upper abdomen prior to starting neoadjuvant treatment and after completion of the standard-of-care CRT including FOLFIRINOX followed by short (10 fractions) or long-term (28 fractions) radiation and capecitabine [32]. Dynamic PET imaging of the upper abdomen was performed for up to 90 min after intravenous (i.v.) injection of the ⁶⁸Ga-CBP8 using a Siemens mMR Biograph 3 Tesla MR/PET scanner. Simultaneous MR images including T1-, T2-, and diffusion-weighted images and multi-phase (including late arterial, portal venous, and delayed phase) contrast-enhanced images of the pancreas were obtained following administration of gadoterate meglumine (0.2 mL/kg) at an injection rate of 2 mL/s, using the institutional standard protocol with a total acquisition time of up to 25 min. PET images were reconstructed after applying the parameters for detector efficiency, decay, dead time, scatter, and MR-based attenuation correction. Image processing and analysis were performed by an abdominal radiologist and a nuclear radiologist with 15 and 8 years of experience in the analysis and interpretation of PET and MRI. The study investigators were blinded to disease status (pre- vs. post-CRT) using the same tools (AMIDE software) to minimize any technique-related variability. Guided by the MR images, an ROI was drawn over the pancreatic tumor, un-involved pancreas, and the descending aorta at the level of the tumor (as blood pool). PET standard uptake values (SUV_mean) of the tumor, pancreas, and blood were calculated over time and compared between the pre-and post-CRT PET scans. The SUV_mean in the tumors and pancreas on pre- and post-CRT PET scans were correlated with the collagen content of diagnostic core and resected tissues.

Patients' demographics including age, gender, race, ethnicity, Eastern Cooperative Oncology Group (ECOG) performance status, initial local staging of the tumor, location of the primary tumor in the pancreas, CA-19-9 level prior to treatment and prior to surgery, neoadjuvant treatment regimen, and type of surgery were reported.

Histological analyses

The extracted tumor and pancreas tissues were fixed in formalin and the paraffin-embedded tissue blocks were cut into 5 μm thick slides. The tissues were stained with hematoxylin and eosin (H&E), Masson Trichrome, and PSR. Immunohistochemical (IHC) staining was performed using methods previously described [31]. The slides were incubated with mouse monoclonal primary antibody for collagen type I (ab88147, Abcam) at 1/50 dilution followed by goat anti-mouse HRP conjugated secondary antibody (ab6789, Abcam) at 1/1000 dilution, and with rabbit monoclonal primary antibody for cleaved caspase-3 (9579S, Cell Signaling) at 1/500 dilution, followed by goat anti-rabbit HRP-conjugated secondary antibody (ab6721) at 1/1000 dilution. The slides were then mounted with Prolong Gold Antifade Reagent and DAPI (ab8961, Abcam). Microscopic evaluation was performed by BioTeK Citation 5 microscopy system. Biomarker quantification was performed using ImageJ software (version 1.5.3.0). Collagen was quantified as collagen proportion area (CPA) defined as the percentage of positive collagen staining over the total tissue area. Cleaved caspase-3 was reported as the percentage of positive staining relative to the total cell number.

For the patients under the feasibility study, slides for the diagnostic core samples (1 H&E and 3 slides stained with PSR) and resected tumor tissues with adjacent un-involved pancreas, if available (1 H&E and 1 PR-stained slide per block, 3-31 blocks per tissue) were obtained. The mean tumor and adjacent pancreas CPA were calculated and compared between the pre- and post-treatment samples. The tissue CPA was correlated with the tissue SUV_mean on the PET.

Hydroxyproline assay

Part of the mouse PDAC and pancreas tissues were immediately flash frozen in liquid nitrogen for measuring Hyp and Pro by high-performance liquid chromatography (HPLC) analysis using an established method and was recorded as amounts per wet weight of the tissue [22]. Collagen content was quantified and reported as the ratio of Hyp/Pro.

Statistical analysis

Statistical analysis was performed using GraphPad Software (version 10, CA, USA). Continuous variables are presented as mean ± standard deviation (SD). Two-tailed paired Student's t-test was performed to compare the means of one group under two different conditions and an unpaired t-test was performed to compare the means of two different groups. ANOVA with multiple comparisons and post hoc Tukey's test was used to compare the mean values among multiple groups. ANOVA with repeated measures was performed to compare the mean values for the same mice over multiple time points. Pearson's correlation coefficient was calculated to examine the relationship between the PET probe uptake values and tissue collagen content (CPA). A P-value of less than 0.05 was considered statistically significant.

Results

In vitro viability assay

Treatment of different PDAC cell lines with different concentrations of FOLFIRINOX demonstrated that PANC-1 and PDAC6 cells had a higher sensitivity to FOLFIRINOX, assessed by the concentration required to kill half the cells with a 48-h incubation, while SU.86.86 cells were resistant to FOLFIRINOX under the same conditions (Figure 1A).

Collagen deposition continuously increases in PDAC in response to FOLFIRINOX

Mouse models of subcutaneously engrafted PDAC were treated with i.v. FOLFIRINOX every 3 days. Tumors and pancreas were extracted prior to, and at 3, 6, 9, 12, 15, or 24 days after starting the treatment (n = 3-8/tumor type and time point). Microscopic evaluation of the extracted PANC-1 and PDAC6 tumors demonstrated an overall decrease in cellularity in H&E stained tissue and increased cleaved caspase-3 marker of apoptosis over 24 days of FOLFIRINOX treatment confirming response. A continuous accumulation of collagen within the tumor ECM was observed in Masson's trichrome, PSR, and Collagen type I IHC stained tissue. The cellularity, apoptosis marker, or collagen deposition did not change in resistant SU.86.86 tumors or normal extracted pancreas tissues (Figure 1B, Figure S1A). The visual assessment of fibrotic response in tissues was confirmed by quantitative evaluation of collagen by measuring CPA in PSR-stained slides and the Hyp/Pro ratio. In PANC-1 tumors, the CPA started to show a significant increase on day 6 compared to baseline (CPA: 5 ± 4% vs. 15 ± 4%, at day 0 vs. day 6, respectively, P = 0.02), with an approximately threefold increase from baseline to day 9 (CPA: 5 ± 4% vs.16 ± 9%, P = 0.006) and a threefold increase from day 9 to day 24 (CPA: 16 ± 9% vs. 53 ± 10%, P < 0.0001) (Figure 1C). In PDAC6, the same overall trend was shown although with a slightly slower fibrotic response compared to PANC-1; the CPA increased twofold on day 9 compared to baseline (CPA: 9 ± 3% vs.18 ± 6%, at day 0 vs. day 9, respectively, P = 0.08) and 2.6 fold from day 9 to day 24 (CAP: 18 ± 6% vs. 51 ± 11 P = 0.0002) (Figure 1C). There was no change to slightly decreased CPA in the FOLFIRINOX resistant SU.86.86 tumors (CPA: 33 ± 9% vs. 23 ± 6% at day 0 vs. day 24 respectively, P = 0.75) and unchanged minimal collagen within the pancreas (CPA: 2 ± 1% vs. 2 ± 1% at day 0 vs. day 24, respectively, P = 0.86) (Figure 1C). The CPA results were confirmed by HPLC analyses for hydroxyproline (Hyp) and proline (Pro) in the tissues. There was an overall increase in the Hyp/Pro ratio in PANC-1 and PDAC6 tumors over 24 days of treatment (n = 3-8 per tumor models and timepoint, Hyp/Pro at day 0 vs. day 24 for PANC-1: 0.22 ± 0.05 vs. 0.42 ± 0.05, P = 0.02; for PDAC6: 0.29 ± 0.02 vs. 0.70 ± 0.22, P = 0.006) and no significant change in Hyp/Pro in SU.86.86 tumors or normal pancreas over 24 days of treatment (P = 0.97 and 0.98, respectively, one-way ANOVA with multiple comparisons and post hoc Tukey test) (Figure 1D). The level of response to treatment was confirmed by IHC with a significant increase in cleaved caspase-3 in the PANC-1 and PDAC6 and no significant change in SU.86.86 tumors (P = 0.003, 0.023, and 0.99, respectively, one-way ANOVA with multiple comparisons and post hoc Tukey test) over 24 days (Figure 1E). Based on these histological and biochemical results, day 9 (after 3 doses of FOLFIRINOX) and day 15 (after 5 doses of FOLFIRINOX) were selected as the time points for in vivo PET imaging experiments in this study.

⁶⁸Ga-CBP8 PET probe specifically binds to tumor collagen in animal models of PDAC

The structure of collagen binding probe ⁶⁸Ga-CBP8 and collagen non-binding, linear peptide control probe ⁶⁸Ga-CNBP are shown in Figure 2A. Ex vivo biodistribution analyses in a group of non-tumor-bearing mice demonstrated rapid renal clearance of both probes by 1 h post-injection (Figure S2A). Residual radioactivity from ⁶⁸Ga-CBP8 was significantly lower than ⁶⁸Ga-CNBP in lung, kidney, and liver (P < 0.05) and not significantly different in blood and other organs. At 4 h post-injection, there was further elimination of both probes from the blood and normal organs with no significant difference in their overall biodistribution pattern (P > 0.05 for different organs) (Figure S2B).

 Figure 1 

Collagen increases in the tumor extracellular matrix in response to chemotherapy in mouse models of human PDAC. (A) Cell viability assay at various concentrations of FOLFIRINOX chemotherapy demonstrating the sensitivity of PDAC6 and PANC-1 cells at 24- and 48-h post-treatment and the relative resistance of SU.86.86 cells under the same conditions (n = 3-6 wells/condition). (B) Representative histological evaluation of pancreas and subcutaneously grown tumor tissues in the nude mice extracted before and at multiple days after treatment with FOLFIRINOX (administered every 3 days) and stained with hematoxylin and eosin (H&E), Masson Trichrome and Picro-Sirius Red (PSR) for collagen, immunohistochemical staining for type I collagen, and cleaved caspase-3 for apoptosis (Scale bar: 200 µm). (C) Quantitative analysis of collagen from PSR stained tissue reported as collagen proportional area (CPA). (D) Measure of collagen on the extracted tumors reported as hydroxyproline-to-proline (Hyp/Pro) ratio. (E) Quantitative immunohistochemical staining of apoptosis marker cleaved caspase-3 in the tumors at multiple time points. Each data point represents one mouse. Data are shown in mean ± SD. P values are the result of one-way ANOVA with multiple comparisons and post hoc Tukey test.

A schematic illustration of the study design is shown in Figure 2B. Dynamic PET imaging of PANC-1 or PDAC6 tumor-bearing mice was performed on consecutive days. On day 1 ⁶⁸Ga-CBP8 or the control probe ⁶⁸Ga-CNBP was administered intravenously, and the next day the other probe was used; the order of probe administration was randomized. There was significantly higher ⁶⁸Ga-CBP8 tumor uptake compared to ⁶⁸Ga-CNBP at 0-60 min post-injection (P < 0.05, paired t-test). The tumor-to-blood uptake ratio of ⁶⁸Ga-CBP8 exceeded 1 by 30 min post-injection and the 30-60 min data collection time interval was chosen for subsequent PET imaging experiments (Figure 2C-D, Figure S3). There was a significant positive correlation between tumor collagen content (CPA) and tumor ⁶⁸Ga-CBP8 PET uptake values, whereas no significant correlation was found with the ⁶⁸Ga-CNBP (R² = 0.67, P = 0.001, and R² = 0.015, P = 0.72, respectively) (Figure 2E). In a separate group of mice engrafted with PANC-1 tumors, PET imaging with ⁶⁸Ga-CBP8 and ⁶⁸Ga-CNBP was performed on two consecutive days at baseline, 9/10, and 15/16 days after treatment with FOLFIRINOX (Figure 3A). There was a significantly higher tumor uptake with ⁶⁸Ga-CBP8 compared with ⁶⁸Ga-CNBP at each time point (P < 0.05, paired t-test). While the tumor uptake with ⁶⁸Ga-CBP8 increased over time (tumor %ID/cc on day 0, 9, 15: 0.87 ± 0.22, 1.35 ± 0.33, 1.79 ± 0.23, P = 0.0006, one-way ANOVA with post hoc test), the ⁶⁸Ga-CNBP PET uptake values did not significantly change (tumor %ID/cc on day 0, 9, 15: 0.50 ± 0.22, 0.71 ± 0.12, 0.71 ± 0.20, P = 0.77, one-way ANOVA) (Figure 3B-C).

 Figure 2 

⁶⁸Ga-CBP8 specifically binds to collagen type 1 in mouse models of PDAC. (A) Structure of the type I collagen binding ⁶⁸Ga-CBP8 and control nonbinding ⁶⁸Ga-CNBP probes. There are 3 NODAGA moieties for potential Ga-68 labeling and the radiolabeled product is a mixture of these three isomers with a representative isomer shown here. (B) Schematic illustration of the study design for testing the specificity of ⁶⁸Ga-CBP8 and control ⁶⁸Ga-CNBP probes in untreated PDAC models based on dynamic PET over two consecutive days. (C) Tumor uptake curves from dynamic PET acquired 0-60 min after intravenous injection of each probe (⁶⁸Ga-CBP8 in blue line and ⁶⁸Ga-CNBP in black line) quantified as the percentage of injected dosage per cc (%ID/cc) (n = 4-7 male nude mice, Data are shown in mean ± SD). (D) Clearance of the ⁶⁸Ga-CBP8 from the blood (red line) over 60 min and tumor-to-blood uptake ratio (green line) reaching above 1 at 30-60 min post-injection (n = 5-6, Data are shown in mean ± SD). (E) Representative Picro-Sirius Red stained tissue of extracted tumors and correlation of collagen proportional area (CPA) with the mean tumor PET uptake values at 30-60 min of imaging with the specific ⁶⁸Ga-CBP8 (R² = 0.67, P = 0.001) and linear control ⁶⁸Ga-CNBP (R² = 0.015, P = 0.72) (each data point represents one mouse). PANC-1 data is shown in orange and PDAC6 in blue color.

 Figure 3 

⁶⁸Ga-CBP8 shows specific changes in type I collagen in response to chemotherapy in mouse models of PDAC. (A) Schematic illustration of study design to demonstrate the specificity of ⁶⁸Ga-CBP8 compared to control ⁶⁸Ga-CNBP PET over multiple days of treatment with FOLFIRINOX (administered every 3 days) in PANC-1 tumor-bearing mice (male nude mice, n = 4-6/group). (B-C) Representative coronal PET images (tumors shown in yellow circle) and quantitative analyses demonstrating a significantly higher uptake of ⁶⁸Ga-CBP8 in the tumors at all time points compared to the control ⁶⁸Ga-CNBP (paired t-test, two-tailed), highlighting the specificity of the probe for collagen I. Data also show an increase in tumor ⁶⁸Ga-CBP8 following FOLFIRINOX treatment but no increase in ⁶⁸Ga-CNBP tumor uptake with treatment. Data are shown in mean ± SD.

⁶⁸Ga-CBP8 PET enables non-invasive monitoring of response to chemotherapy in PDAC mouse models

⁶⁸Ga-CBP8 uptake values continuously increased in response to duration of FOLFIRNINOX treatment in FOLFIRINOX-sensitive PANC-1 tumors (%ID/cc: 0.8 ± 0.2 vs. 1.1 ± 0.3 vs. 1.9 ± 0.2, in day 0 vs. day 9 vs. day 15, respectively, P < 0.05 among time points, ANOVA with multiple comparisons, n = 5), and FOLFIRINOX-sensitive PDAC6 tumors (%ID/cc: 0.68 ± 0.32 vs. 1.1 ± 0.52 vs. 1.32 ± 0.58, n = 6, P < 0.05 among time points, ANOVA with multiple comparisons). On the other hand, no significant change was observed in ⁶⁸Ga-CBP8 PET tumor values in vehicle treated or in FOLFIRINOX treated resistant SU.86.86 tumors among different time points (P > 0.05, n = 4-8/group) (Figure 4A-C, Figure S4). There was a significant tumor growth reduction in PANC-1 and PDAC6 tumors in response to FOLFIRINOX compared to their vehicle treated groups, but not for SU.86.86 tumors (day 24 tumor volume mm³ for FOLFIRINOX vs. vehicle: 116 ± 49 vs. 964 ± 491, P = 0.0116 for PANC-1, 183 ± 66 vs. 936 ± 403, P = 0.0011 for PDAC6, and 909 ± 311 vs. 1074 ± 354, P = 0.39 in SU.86.86, unpaired t-test) (Figure 4D).

⁶⁸Ga-CBP8 specifically binds to human PDAC ex vivo

Surgically resected tissues from patients who completed standard 8 cycles of pre-operative FOLFIRINOX followed by CRT (n = 8, M/F: 3/5, age: 56 - 82 y) and patients who underwent upfront resection of their PDAC (n = 8, M/F: 3/5, age: 58 - 78 y) were incubated with ⁶⁸Ga-CBP8 or ⁶⁸Ga-CNBP and assessed by autoradiography (Figure 5A). There was significantly higher ⁶⁸Ga-CBP8 binding in treated compared to untreated PDAC tissues (P < 0.0001, unpaired t-test) and when compared to each patient's matched normal pancreas (P < 0.0001, unpaired t-test). No significant difference in ⁶⁸Ga-CBP8 was observed between the normal uninvolved pancreas tissues of treated and untreated patients (P = 0.98, unpaired t-test) (Figure 5B-D). The control probe ⁶⁸Ga-CNBP was not sensitive to tumor collagen in either group of tissues and the retained activity was not significantly different between the treated and untreated tissues (P = 0.71 and 0.66 in untreated vs. treated PDAC and pancreas tissues respectively) (Figure 5B,C,E). Histological evaluation of the tissues showed an increased collagen deposition in the tumors in response to CRT (CPA: 56.3 ± 11% vs. 31.7 ± 17.2%, P = 0.0057 in treated vs. untreated PDAC respectively), while it remained low and not significantly changed in the adjacent pancreas tissues between the treated and untreated tissues (CPA: 11.2 ± 6.4% vs. 14.5 ± 8.4%, P = 0.39) (Figure 5F-G). A significant positive correlation was noted between ⁶⁸Ga-CBP8 signal in autoradiography and the amount of tumor or pancreas collagen assessed by CPA (R²= 0.6, P < 0.0001), while no such correlation was observed with ⁶⁸Ga-CNBP (R²= 0.05, P = 0.18) (Figure 5H). Together these results confirm the specificity of ⁶⁸Ga-CBP8 to type I collagen in human PDAC.

 Figure 4 

⁶⁸Ga-CBP8 enables monitoring of the response to chemotherapy in mouse models of human PDAC and differentiates responders from non-responders. (A) Schematic study design. (B) Representative coronal PET images of the nude mice with PANC-1 and SU.86.86 tumors imaged from 30-60 min after injection of ⁶⁸Ga-CBP8 at days 0, 9, and 15 after treatment with intravenous FOLFIRINOX or vehicle (tumors shown in yellow circle). (C) Quantitative analyses of ⁶⁸Ga-CBP PET tumor uptake at days 0, 9, and 15 of treatment with FOLFIRINOX or vehicle (n = 4-8/group, ANOVA with multiple comparisons and post hoc Tukey test). (D) Tumor volume curves over 24 days of treatment with FOLFIRINOX or vehicle. Data are shown in mean ± SD.

 Figure 5 

⁶⁸Ga-CBP8 detects fibrosis and measures response to neoadjuvant chemoradiotherapy in resected human pancreatic tumor tissues. (A) Schematic illustration of human pancreatic ductal adenocarcinoma (PDAC) and pancreas tissue preparation, incubation with collagen-specific ⁶⁸Ga-CBP8 and control ⁶⁸Ga-CNBP probes, and autoradiography. (B) Representative autoradiography images of fresh resected human tissues and (C) heatmap of the autoradiography signal. (D-E) Quantitative comparison of autoradiography signal in the treated and untreated PDAC tissues and the patients' matched adjacent uninvolved pancreas (P) for ⁶⁸Ga-CBP8 (D) and ⁶⁸Ga-CNBP (E) (n = 8/group, unpaired t-test, two-tailed). (F) Representative H&E, Picro-Sirius Red (PSR), and type I collagen immunohistochemical staining of human tissues (scale bar: 200 µm). (G) Quantitative comparison of collagen proportional area (CPA) from PSR stained slides of human tumor and pancreas tissues (n = 8/group, unpaired t-test, two-tailed). (H) Correlation of the ⁶⁸Ga-CBP8 or ⁶⁸Ga-CNBP autoradiography signal with CPA. Each data point represents one tissue. RT: room temperature, a.u: arbitrary unit.

⁶⁸Ga-CBP8 PET/MRI of PDAC patients

Eight patients (all male, white non-Hispanic, mean age ± SD: 60 ± 5 y, range: 49 - 65 y) with newly diagnosed PDAC (6 with borderline resectable and 2 with locally advanced PDAC) were enrolled in this feasibility study. Patients underwent dynamic PET for 47-90 min after administration of ⁶⁸Ga-CBP8 probe (122-281 MBq) followed by standard contrast-enhanced MRI of the pancreas prior to starting the neoadjuvant treatment. The first patient declined the repeat pre-operative scan, and the fifth patient was unable to return for repeat scan due to an accelerated surgery schedule. The last patient showed local progression of the primary tumor and received additional cycles of FOLFIRINOX and gemcitabine/nab-paclitaxel chemotherapy therefore surgery was not planned. Five (5/8) patients underwent repeat PET/MRI after completion of CRT (repeat PET duration: 30 - 90 min, administered dosage:128 - 220 MBq). All patients tolerated the scan and administration of the radiopharmaceutical without any adverse effects. The CA-19-9 level decreased in all the patients during the treatment, and tumors decreased in size as measured by standard CT scans before and after the completion of treatment. Two patients received losartan during the treatment; one of which showed vascular involvement of the primary tumor at laparotomy and the other one showed fibrosis without any evident live tumor on the intra-operative biopsy of the tumor. These two patients underwent intra-operative radiation followed by gastrojejunostomy. The remaining patients underwent the Whipple procedure (Table S1 and Table S2).

Representative standard CT and ⁶⁸Ga-CBP8 PET/MRI of a patient pre- and post-CRT are shown in Figure 6A. PET image analyses at both pre-CRT and post-CRT visits showed rapid renal clearance of the ⁶⁸Ga-CBP8 probe from the blood and normal pancreas. By 15-30 min, the blood SUV_mean reached the value of the uninvolved pancreas SUV_mean (Figure 6B). The tumor SUV_mean remained significantly higher than the pancreas at both pre-CRT (mean SUV_mean at 30-60 min: 2.35 ± 0.36 vs. 1.99 ± 0.25, P = 0.036, unpaired t-test, two-tailed) and post-CRT scans (2.83 ± 0.30 vs. 1.75 ± 0.43, P = 0.002, unpaired t-test, two-tailed) (Figure 6C). In the five patients who underwent a repeat PET/MRI scan, the tumor was reduced in size on concurrent MRI and the PET probe uptake values significantly increased in the treated compared to untreated tumors (SUV_mean: 2.83 ± 0.30 vs. 2.25 ± 0.41, P = 0.01, paired t-test) whereas the uptake in the uninvolved pancreas did not significantly change (SUV_mean: 1.76 ± 0.43 vs. 1.94 ± 0.24, P = 0.41, in treated vs untreated timepoints, paired t-test) (Figure 6D).

Histological evaluation of the available tumors and the available immediately adjacent non-cancerous pancreas tissues demonstrated higher collagen content (CPA) in the tumors compared with the adjacent pancreas (59 ± 9% vs. 17 ± 11%, P < 0.0001, in treated tumors vs. uninvolved adjacent pancreas respectively, unpaired t-test, two-tailed) (Figure 6E). Response to treatment was confirmed on post-surgical histological tissue microscopic evaluations. A comparison of the initial core biopsy and resected tumor slides showed a significantly higher tumor CPA in the treated tissues (56 ± 6% vs. 32 ± 5%, P = 0.005, in 4 patients with available pre- and post-CRT tissues, paired t-test, and 59 ± 9% vs. 30 ± 9%, P = 0.0005, in all available tissues, n = 6 untreated and 5 treated, unpaired t-test) (Figure 6F). There was a significant positive correlation between the tissue CPA and PET SUV_mean of PDAC and pancreas (R² = 0.54, P = 0.0007) (Figure 6G).

Discussion

In this study, we demonstrated that ⁶⁸Ga-CBP8 PET probe specifically targets and quantifies the dynamic changes of type I collagen in the PDAC ECM in both pre-clinical and clinical settings. The results of our first-in-human feasibility study suggest that ⁶⁸Ga-CBP8 PET can provide a unique tool to non-invasively monitor treatment response in patients with PDAC. Fibrotic stroma is highly abundant in PDAC and is a major promotor of tumorigenesis, local invasion, and metastasis [18, 33]. Type I collagen is the dominant component of tumor fibrosis and increases in response to chemotherapy [14]. We previously demonstrated that higher collagen deposition in tumors following CRT is associated with longer overall and progression-free survival independent of other clinicopathologic and demographic variables in PDAC patients and therefore, changes in tumor collagen could be used as a predictor of clinical outcomes [14]. Here, we validated ⁶⁸Ga-CBP8 PET in multiple mouse models of human PDAC with different levels of sensitivity to chemotherapy and translated this technique to PDAC patients for the first time. ⁶⁸Ga-CBP8 and analogous MRI probes where the Ga-68 is replaced with chelated gadolinium have been shown to detect, stage, and monitor fibrotic changes in animal models of cardiac, hepatic, and pulmonary fibrosis [23, 34-38]. We recently showed the favorable biodistribution and dosimetry of ⁶⁸Ga-CBP8 in healthy volunteers (NCT03535545) [26] and its ability to detect increased collagen in patients with pulmonary fibrosis [25, 27]. The probe is currently under investigation in multiple clinical trials in different fibrotic conditions (NCT04485286, NCT03535545).

Given the overall poor prognosis of PDAC and high toxicity of standard chemotherapy regimens, more reliable imaging methods are required for differentiating the responders from non-responders and allowing clinicians with timely clinical management decisions to personalize the treatment strategies. Conventional CT and MRI used in daily clinical practice have limited abilities to provide such guidance as the changes in tumor morphology and size often lag behind the changes in their molecular signatures [10-13]. Additionally, current standard methods for evaluation of PDAC response to neoadjuvant therapy such as radiographic response evaluation criteria in solid tumors (RECIST) and pathologic response grading, fail to predict survival in PDAC [10, 15, 39].

 Figure 6 

First-in-human evaluation of type I collagen PET in patients with PDAC. (A) Representative axial images of standard-of-care iodinated contrast-enhanced computed tomography (CT) on late arterial phase, gadolinium-enhanced magnetic resonance image (MRI) on portal venous phase, ⁶⁸Ga-CBP8 PET at 30-45 min post-injection, and fused PET and T1-weighted MR images in the axial plane are shown for a subject before and after standard chemoradiotherapy (CRT). PDAC tumor is shown with a white arrow. (B) Evaluation of dynamic PET from 0-90 min after injection of the ⁶⁸Ga-CBP8 shows rapid clearance of the probe from the blood (dashed red line), with blood SUV_mean reaching that of the uninvolved pancreas SUV_mean (blue line) at 15-30 min post-injection. Uptake to untreated PDAC is shown with black and to treated PDAC with dark red line. Data is shown in mean ± SEM. (C) The tumor SUV_mean is significantly higher than the pancreas at both pre-CRT and post-CRT scans (paired t-test). (D) PET uptake values at 30-60 min post-injection for the five patients who underwent PET scans at both time points show increased tumor SUV_mean in response to neoadjuvant CRT paired t-test). (E) Representative H&E and Picro-Sirius Red staining of the diagnostic core of tumor (T), and resected treated tumor and adjacent pancreas (P) tissues. (F) Quantitative analyses of histology show higher CPA in the treated compared to untreated tumors (** P = 0.0005 for all available tissues using unpaired t-test; P = 0.005 for 4 patients with available pre- and post-CRT tissues using paired t-test). (G) Significant positive correlation between the tissue collagen on histology (CPA) and SUV_mean.

While changes in tumor metabolism on ¹⁸F-FDG PET have demonstrated valuable insights for determination of treatment response when combined with anatomical and/or biochemical assessments in pancreatic cancer, the utility of ¹⁸F-FDG PET has shown to be limited in multiple scenarios [40-42]. Examples include variability of tumor ¹⁸F-FDG uptake in PDAC and other types of pancreatic tumors at baseline, challenges in detection of small lesions, difficulties in assessment of disease burden particularly in patients with peritoneal carcinomatosis, and confounding factors such as uptake in infectious and inflammatory conditions such as chronic pancreatitis, among others [40, 43, 44]. Our study suggests that collagen PET could address these challenges for evaluation of response to treatment in PDAC patients.

We observed that collagen continuously increases within the ECM of chemotherapy-sensitive human PDAC xenografts as well as in the resected tissues from patients who responded to neoadjuvant CRT and that this change was accurately measured using collagen PET. Our histological findings align with previously published studies, where the collagen content showed a significant increase in pancreatic tumors treated with FOLFIRINOX or Gemcitabine [14, 20, 45]. While some studies have suggested that a dense fibrotic tumor stroma at baseline can decrease the penetration and efficacy of medications [18, 19], others have shown that higher amounts of type I collagen and other fibrosis markers in untreated PDAC tissues correlate with longer patient survival [46-48]. While we focused on quantifying the change in collagen deposition in this work, further investigation is necessary to determine whether the pre-treatment collagen and tumor desmoplasia are associated with neoadjuvant treatment response. The results of our study suggest that the change in tumor collagen due to therapeutics is a continuous and dynamic process, and a comparison of pre-and post-treatment collagen PET could be used as a non-invasive method for measuring this dynamic change and differentiating responders from non-responders. ⁶⁸Ga-CBP8 PET has multiple advantages for PDAC over current investigational imaging techniques. While tumor enhancement patterns with iodinated contrast-enhanced CT and gadolinium-enhanced MRI have been suggested to differ in fibrotic tumors, a reliable evaluation method is not established [49]. Limited number of studies have focused on changes in the b-values in restricted diffusion-weighted MRI and changes in tissue elasticity on elastography in fibrotic tumors, however, these methods still need to be validated for early assessment of treatment outcome [50, 51]. Fibroblast activation protein targeting PET probes have shown superior accuracy for detection of PDAC in multiple clinical trials [52, 53], although the ability of this technique for evaluation of treatment response is under investigation. We anticipate that ⁶⁸Ga-CBP8 PET can serve as a reliable and non-invasive quantitative surrogate of PDAC tumor fibrosis to guide management decisions for neoadjuvant therapy and assess treatment response. One of the major benefits of ⁶⁸Ga-CBP8 PET is the possibility of simultaneous acquisition of information on the collagen content as a biomarker of response to treatment, in addition to the anatomic morphological changes assessed by CT or MRI. The rapid renal clearance and plasma stability of ⁶⁸Ga-CBP8 and the 68 minute half-life of Ga-68 result in overall low radiation exposure to subjects allowing for serial PET imaging to monitor treatment response [54]. Our study has multiple limitations. The preclinical studies were performed in subcutaneous human PDAC xenografts to avoid the interference of PET signal bleeding from the kidneys to the adjacent pancreas in small animals, and therefore, orthotopic mouse modes of PDAC could not be used. The mouse models of human PDAC with variable levels of sensitivity to chemotherapy were developed in immunocompromised mice and therefore, the interaction of host stroma and PDAC cells and lack of the immunocompetent tumor microenvironment may have affected the degree of fibrosis in the animal models. However, we observed a similar trend of collagen change in immunocompetent human experiments. While ⁶⁸Ga-CBP8 PET was able to differentiate treatment responders from non-responders in animal models and resected human tissues, all the patients who completed pre- and post-treatment scans showed clinical and histological response to standard neoadjuvant treatment. Therefore, we were unable to evaluate the PET findings in patients resistant to standard chemotherapy. Further evaluation of ⁶⁸Ga-CBP8 PET in larger scale clinical trials with a diverse patient population in both local and metastatic settings and with variable response to treatment is required to establish the utility and application of this technique in clinical practice.

In conclusion, our study shows that collagen PET provides a surrogate of treatment response in PDAC. This unique image-guided approach could significantly improve the quality of care by reducing the need for invasive procedures such as exploratory laparotomy and biopsy in the future. Collagen PET could also enable future clinical trials that use imaging of tumor fibrosis for early determination of treatment response and outcomes to accelerate drug development, particularly in the realm of anti-fibrotics. We anticipate collagen PET to improve cohort enrichment strategies and patient selection for trials in PDAC and other fibrotic neoplasms.

Abbreviations

PDAC: Pancreatic ductal adenocarcinoma; CRT: chemoradiotherapy; CT: Computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; ROI: region of interest; %ID/g: percentage of injected dose per gram; ECOG: Eastern Cooperative Oncology Group; IHC: immunohistochemistry; CPA: collagen proportion area; HPLC: high-performance liquid chromatography; SD: standard deviation; Hyp: hydroxyproline; Pro: proline; PSR: Pcirosirius red.

Supplementary Material

Supplementary figures and table.

Acknowledgements

The authors are grateful to Staci Mangini and Isha Metha, MD for helping with scan coordination and IRB regulatory documentation, Bahar Ataeinia, MD for helping with cell culture, Pamela Pantazopolous for helping with tissue staining.

Funding

This study was supported by National Cancer Institute: K08CA259626 (SAE) and K08CA249047 (PH); Ralph Schaleger Fellowship Grant from Massachusetts General Hospital (SAE); National Heart Lung and Blood Institute: R01HL153606 (PC); National Institutes of Health Office of the Director: S10OD032138, S10OD028499, and S10OD023503 (PC).

Author contributions

Conceptualization: SAE, PC, HM, CW, TSH, KKT.

Methodology and investigation: probe synthesis and quality assessment: PC, SAE, HM, SS, pre-clinical data acquisition and analysis: SAE, HM, SK, SR, PH, PC, JW, CC, IZ, NR, Ex vivo tissue staining and analyses: SAE, SK, PH, GMB, KKT, MQ, CD, HM, Human subject recruitment and clinical data analyses: SAE, CW, ML, IZ, TSH, CF, HR, MQ, PP, ARP, UM, CD, KKT, PH, OC, EA, Human PET/MRI acquisition and analyses: SAE, CC, EA, CD, OC, UM, PH, ML.

Funding acquisition: SAE, PC.

Supervision: SAE, HM, PC, CC, ML, UM, PH.

Writing - original draft: SAE, PC.

Writing - review & editing: all authors.

Competing Interests

PC has equity in and is a consultant to Collagen Medical LLC, has equity in Reveal Pharmaceuticals Inc., and has research support from Transcode Therapeutics and Pliant Therapeutics. PC is a co-inventor of US Patent 10,471,162 which covers ⁶⁸Ga-CBP8 and is assigned to the General Hospital Corporation. SE has research support from Sofie Biosciences, Telix, and Novartis Pharmaceuticals. ARP has held Equity in C2i Genomics, XGenomes, Cadex, Vionix and Parithera. In the last 36 months, she has served as an advisor/consultant for Eli Lilly, Mirati, Pfizer, Inivata, Biofidelity, Checkmate Pharmaceuticals, FMI, Guardant, Abbvie, Bayer, Delcath, Taiho, CVS, Value Analytics Lab, Seagen, Saga, AZ, Scare Inc, Illumina, Taiho, Hookipa, Kahar Medical, Xilio Therapeutics, Sirtex, Takeda, and Science For America. She receives fees from Up to Date. She has received travel fees from Karkinos Healthcare. She has been on the DSMC for a Roche study and on the Steering Committee for Exilixis. She has received research funding to the Institution from PureTech, PMV Pharmaceuticals, Plexxicon, Takeda, BMS, Mirati, Novartis, Erasca, Genentech, Daiichi Sankyo, Syndax, Revolution Medicine and Parthenon. UM is a co-founder, shareholder, and consultant (Scientific Advisory Board) of CytoSite BioPharma. TSH is a consultant for Synthetic Biologics, Novocure, Boston Scientific, Neogenomics, Merck, GSK, NextCure, serves on the advisory board of PanTher Therapeutics (Equity), and Lustgarten Foundation, and has received research funding from Taiho, Astra-Zeneca, BMS, GSK, ItraOp and Ipsen. GMB has sponsored research agreements through her institution with: Olink Proteomics, Teiko Bio, InterVenn Biosciences, Palleon Pharmaceuticals. She served on advisory boards for Iovance, Merck, Nektar Therapeutics, Novartis, and Ankyra Therapeutics. She consults for Merck, InterVenn Biosciences, Iovance, and Ankyra Therapeutics. She holds equity in Ankyra Therapeutics. Other authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7-30

2. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10:10-27

3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-21

4. Arvold ND, Niemierko A, Mamon HJ, Fernandez-del Castillo C, Hong TS. Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys. 2011;80:1383-90

5. Seufferlein T, Bachet JB, Van Cutsem E, Rougier P, Group EGW. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii33-40

6. Versteijne E, van Eijck CH, Punt CJ, Suker M, Zwinderman AH, Dohmen MA. et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials. 2016;17:127

7. Artinyan A, Anaya DA, McKenzie S, Ellenhorn JD, Kim J. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer. 2011;117:2044-9

8. Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA. et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18:543-8

9. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-25

10. Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI. et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261:12-7

11. Cassinotto C, Cortade J, Belleannee G, Lapuyade B, Terrebonne E, Vendrely V. et al. An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol. 2013;82:589-93

12. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R. et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749-56

13. Takahashi H, Ohigashi H, Ishikawa O, Eguchi H, Gotoh K, Yamada T. et al. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg. 2010;251:461-9

14. Erstad DJ, Sojoodi M, Taylor MS, Jordan VC, Farrar CT, Axtell AL. et al. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Clin Cancer Res. 2020;26:5007-18

15. Chawla A, Wo J, Castillo CF, Ferrone CR, Ryan DP, Hong TS. et al. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Pancreatology. 2020;20:691-7

16. Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V. et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg. 2013;257:731-6

17. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE. et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg. 2006;10:1338-45 discussion 45-6

18. Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019;18:14

19. Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014;40:118-28

20. Ma H, Esfahani SA, Krishna S, Ataeinia B, Zhou IY, Rotile NJ. et al. Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer. Cancer Res. 2024;84:2549-60

21. Desogere P, Tapias LF, Rietz TA, Rotile N, Blasi F, Day H. et al. Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis. J Nucl Med. 2017;58:1991-6

22. Desogere P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK. et al. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med. 2017;9:eaaf4696

23. Farrar CT, Gale EM, Kennan R, Ramsay I, Masia R, Arora G. et al. CM-101: Type I Collagen-targeted MR Imaging Probe for Detection of Liver Fibrosis. Radiology. 2018;287:581-589

24. Fuchs BC, Wang H, Yang Y, Wei L, Polasek M, Schuhle DT. et al. Molecular MRI of collagen to diagnose and stage liver fibrosis. J Hepatol. 2013;59:992-8

25. Montesi SB, Izquierdo-Garcia D, Desogere P, Abston E, Liang LL, Digumarthy S. et al. Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies. Am J Respir Crit Care Med. 2019;200:258-61

26. Izquierdo-Garcia D, Desogere P, Fur ML, Shuvaev S, Zhou IY, Ramsay I. et al. Biodistribution, Dosimetry, and Pharmacokinetics of (68)Ga-CBP8: A Type I Collagen-Targeted PET Probe. J Nucl Med. 2023;64:775-81

27. Abston E, Zhou IY, Saenger JA, Shuvaev S, Akam E, Esfahani SA. et al. Noninvasive Quantification of Radiation-Induced Lung Injury Using a Targeted Molecular Imaging Probe. Int J Radiat Oncol Biol Phys. 2024;118:1228-39

28. Michelakos T, Cai L, Villani V, Sabbatino F, Kontos F, Fernandez-Del Castillo C. et al. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. J Natl Cancer Inst. 2021;113:182-91

29. Esfahani SA, Callahan C, Rotile NJ, Heidari P, Mahmood U, Caravan PD. et al. Hyperpolarized [1-(13)C]Pyruvate Magnetic Resonance Spectroscopic Imaging for Evaluation of Early Response to Tyrosine Kinase Inhibition Therapy in Gastric Cancer. Mol Imaging Biol. 2022;24:769-79

30. Esfahani SA, De Aguiar Ferreira C, Summer P, Mahmood U, Heidari P. Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors. J Nucl Med. 2023;64:1056-61

31. Esfahani SA, de Aguiar Ferreira C, Rotile NJ, Ataeinia B, Krishna S, Catalano OA. et al. HER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer. Mol Imaging Biol. 2023;25:353-62

32. Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC. et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018;4:963-9

33. Polasek M, Yang Y, Schuhle DT, Yaseen MA, Kim YR, Sung YS. et al. Molecular MR imaging of fibrosis in a mouse model of pancreatic cancer. Sci Rep. 2017;7:8114

34. Caravan P, Yang Y, Zachariah R, Schmitt A, Mino-Kenudson M, Chen HH. et al. Molecular magnetic resonance imaging of pulmonary fibrosis in mice. Am J Respir Cell Mol Biol. 2013;49:1120-6

35. Helm PA, Caravan P, French BA, Jacques V, Shen L, Xu Y. et al. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology. 2008;247:788-96

36. Zhou IY, Clavijo Jordan V, Rotile NJ, Akam E, Krishnan S, Arora G. et al. Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. Radiology. 2020;296:67-75

37. Polasek M, Fuchs BC, Uppal R, Schuhle DT, Alford JK, Loving GS. et al. Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. J Hepatol. 2012;57:549-55

38. Farrar CT, DePeralta DK, Day H, Rietz TA, Wei L, Lauwers GY. et al. 3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model. J Hepatol. 2015;63:689-96

39. Neyaz A, Tabb ES, Shih A, Zhao Q, Shroff S, Taylor MS. et al. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Histopathology. 2020;77:35-45

40. Bang S, Chung HW, Park SW, Chung JB, Yun M, Lee JD. et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006;40:923-9

41. Abdelrahman AM, Goenka AH, Alva-Ruiz R, Yonkus JA, Leiting JL, Graham RP. et al. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. J Natl Compr Canc Netw. 2022;20:1023-32 e3

42. Panda A, Garg I, Truty MJ, Kline TL, Johnson MP, Ehman EC. et al. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival. AJR Am J Roentgenol. 2021;217:730-40

43. Ghaneh P, Hanson R, Titman A, Lancaster G, Plumpton C, Lloyd-Williams H. et al. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. Health Technol Assess. 2018;22:1-114

44. Yoo J, Lee JM, Joo I, Lee DH, Yoon JH, Yu MH. et al. Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, (18)F-FDG PET/MRI and CA 19-9. Cancer Imaging. 2023;23:49

45. Park JK, Kim Y, Kim H, Jeon J, Kim TW, Park JH. et al. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget. 2016;7:75081-93

46. Wang LM, Silva MA, D'Costa Z, Bockelmann R, Soonawalla Z, Liu S. et al. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7:4183-94

47. Torphy RJ, Wang Z, True-Yasaki A, Volmar KE, Rashid N, Yeh B. et al. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. JCO Precis Oncol. 2018;2018:PO.17.00121

48. Erkan M, Michalski CW, Rieder S, Reiser-Erkan C, Abiatari I, Kolb A. et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2008;6:1155-61

49. Hattori Y, Gabata T, Matsui O, Mochizuki K, Kitagawa H, Kayahara M. et al. Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: correlation with angiogenesis and fibrosis. World J Gastroenterol. 2009;15:3114-21

50. De Robertis R, Tinazzi Martini P, Demozzi E, Dal Corso F, Bassi C, Pederzoli P. et al. Diffusion-weighted imaging of pancreatic cancer. World J Radiol. 2015;7:319-28

51. Yoshikawa M, Ishikawa T, Ohno E, Iida T, Furukawa K, Nakamura M. et al. Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer. Sci Rep. 2021;11:7409

52. Koerber SA, Rohrich M, Walkenbach L, Liermann J, Choyke PL, Fink C. et al. Impact of (68)Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers. J Nucl Med. 2023;64:1712-20

53. Novruzov E, Giesel FL, Mori Y, Choyke PL, Dabir M, Mamlins E. et al. Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [(18)F]FAPI-74 with [(18)F]FDG in Patients with PDAC: A Prospective Exploratory Study. Cancers (Basel). 2023;15:2798

54. Esfahani SA, Salcedo S, Heidari P, Catalano OA, Pauplis R, Hesterman J. et al. A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of (68)Ga-DOTATOC in healthy volunteers. Am J Nucl Med Mol Imaging. 2017;7:53-62

Author contact

Corresponding author: Shadi Abdar Esfahani, MD, MPH, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, 55 Fruit St, White 427J, Boston, MA, 02114. Email: Esfahani.shadiharvard.edu; Tel.: 617-726-1758.

Received 2024-6-26
Accepted 2024-8-28
Published 2024-9-9

Citation styles

©2024 Ivyspring International Publisher. Terms of use